Atlas Trials

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

Clinical trial NCT07401381 · RECRUITING

Trial details

NCT number
NCT07401381
Sponsor
Rovi Pharmaceuticals Laboratories
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Hormone Receptor Positive Early Breast Cancer
Start date
2026-06-08
Primary completion
2028-05-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.